NorthWest Biotherapeutics Inc (NWBO)

[Evaluate]

You wrote:

Another time clue, although no one here might think so, could be Mike Scott’s recent comment that the GMP specials certification occurred ahead of SCHEDULE.

Mike Scott also indicated that the Sawston facility is "on an exponential growth curve" less than a year after opening its door.
The facility is already being used to good effect by Advent on behalf of NW Bio and various other clients - and the partners haven't even started any external marketing yet.
The facility will eventually be developed to expand production and capability in a number of specialisms, from tailored cancer vaccines to a raft of personalized cancer treatments.
The MHRA licence enables the manufacture of DCVax-L products to get underway at Sawston .... the licence also permits the import and GMP manufacture of other cell therapy products ...
As Business Weekly reported when NW announced the Cambridge opportunity, the Maryland company is working on a cancer vaccine for Glioblastoma Multiforme ... with Phase III data expected soon.
This therapy has been in development for a long time and it is finally getting closer to reaching the people who can potentially benefit.
To maximize overall potential capacity of the Sawston facility, Advent is actively recruiting third party clients interested in production of bespoke and personalized cell therapy products.
Sawston can also store human tissue samples and cells for external enterprises and is in discussion with local and national companies about this capability.
Scott has identified huge and growing international demand for exactly the type and variety of facilities Advent and NW Bio can supply - over and above the manufacture of their own product portfolio.

I get the impression that the Sawston facility will be bringing in some nice additional revenues (besides the manufacture of DCVax).

Page 20 - https://epaper.businessweekly.co.uk/html5/reader/production/default.aspx?pubname=&pubid=73060283-e40e-4de5-8fed-64ba0bf97eab